Your browser doesn't support javascript.
loading
A Dutch phase III randomized multicenter trial: whole brain radiotherapy versus stereotactic radiotherapy for 4-10 brain metastases.
Hartgerink, Dianne; Bruynzeel, Anna; Eekers, Danielle; Swinnen, Ans; Hurkmans, Coen; Wiggenraad, Ruud; Swaak-Kragten, Annemarie; Dieleman, Edith; van der Toorn, Peter-Paul; Oei, Bing; van Veelen, Lieneke; Verhoeff, Joost; Lagerwaard, Frank; de Ruysscher, Dirk; Lambin, Philippe; Zindler, Jaap.
Afiliación
  • Hartgerink D; Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical Centre+, Maastricht, the Netherlands.
  • Bruynzeel A; Department of Radiation Oncology, Amsterdam University Medical Centers, the Netherlands.
  • Eekers D; Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical Centre+, Maastricht, the Netherlands.
  • Swinnen A; Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical Centre+, Maastricht, the Netherlands.
  • Hurkmans C; Department of Radiation Oncology, Catharina Hospital, Eindhoven, the Netherlands.
  • Wiggenraad R; Department of Radiation Oncology, Haaglanden Medical Center, the Netherlands.
  • Swaak-Kragten A; Department of Radiation Oncology, Erasmus MC, Rotterdam, the Netherlands.
  • Dieleman E; Department of Radiation Oncology, Amsterdam University Medical Centers, the Netherlands.
  • van der Toorn PP; Department of Radiation Oncology, Catharina Hospital, Eindhoven, the Netherlands.
  • Oei B; Department of Radiation Oncology, Verbeeten Institute Tilburg, the Netherlands.
  • van Veelen L; Department of Radiation Oncology, Zuid-West Radiotherapy Institute Vlissingen, the Netherlands.
  • Verhoeff J; Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Lagerwaard F; Department of Radiation Oncology, Amsterdam University Medical Centers, the Netherlands.
  • de Ruysscher D; Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical Centre+, Maastricht, the Netherlands.
  • Lambin P; Department of Precision Medicine, The M-Lab, GROW - School for Oncology and Developmental Biology, Maastricht Comprehensive Cancer Centre, Maastricht University, Maastricht, the Netherlands.
  • Zindler J; Department of Radiation Oncology, Haaglanden MC, Den Haag, the Netherlands.
Neurooncol Adv ; 3(1): vdab021, 2021.
Article en En | MEDLINE | ID: mdl-33738451
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Neurooncol Adv Año: 2021 Tipo del documento: Article País de afiliación: Países Bajos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Neurooncol Adv Año: 2021 Tipo del documento: Article País de afiliación: Países Bajos